Drug Profile
Research programme: therapeutic cancer vaccines - Redbiotec
Alternative Names: RBT 401; RBT 402Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Redbiotec
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in Switzerland (Parenteral)
- 18 Jan 2011 Early research in Cancer in Switzerland (Parenteral)